High-Premium Buyouts Continue In Hepatitis C Space; Are Idenix And Achillion Next?
Executive Summary
Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.
You may also be interested in...
BioCryst Joins HCV Race With $101M Presidio Merger
BioCryst’s proposed merger with Presidio will give the company an instant HCV pipeline. Albeit early-stage, the variety of the drugs could give the company a strong hand against other players in the field.
Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”
In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech’s plans are rooted in an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.
Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”
In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech could do so with an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.